Organization
IQVIA, Amsterdam, Netherlands
13 abstracts
Abstract
Health-related quality of life (HRQoL), functioning, and symptoms with odronextamab monotherapy in patients (pts) with relapsed or refractory follicular lymphoma (R/R FL) by POD24 status in the ELM-2 study.Org: IQVIA, Amsterdam, Netherlands,
Abstract
Results from the follicular lymphoma (FL) outcomes in patients (pts) with relapsed/refractory (R/R) disease treated with systemic therapy in a real-world assessment (FLORA) study.Org: Regeneron Pharmaceuticals, Inc., IQVIA, Amsterdam, Netherlands,
Abstract
Usage pattern of anticoagulants in oncology patients receiving active anticancer therapies in Europe and Asia.Org: IQVIA, Amsterdam, Netherlands, London Regional Cancer Center, Madrid, Spain, Spain, Chicago, IL,
Abstract
Health-related quality of life (HRQoL) of risk-based patient subgroups with advanced renal cell cancer (aRCC) treated with nivolumab plus cabozantinib (NIVO+CABO) vs sunitinib (SUN) in the CheckMate 9ER trial.Org: Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School, Boston, MA, Bristol Myers Squibb, Princeton, NJ, Exelixis, Inc., Alameda, CA, IQVIA, Amsterdam, Netherlands,
Abstract
Use of real-world evidence to benchmark clinical trial results: A case study in von Hippel-Lindau (VHL) disease.Org: National Cancer Institute, Vilnius, Lithuania, Merck & Co., Inc., IQVIA, Amsterdam, Netherlands, National Cancer Institute/National Institutes of Health,
Abstract
Enrolling patients in Cardiac Amyloid Reaching for Extended Survival (CARES) trials: Two placebo-controlled, double-blind, randomized, international phase 3 trials assessing CAEL-101 in patients with Mayo stage IIIa or stage IIIb AL amyloidosis.Org: Stanford Cancer Center, University of Pavia, IQVIA, Amsterdam, Netherlands, Alexion Pharmaceuticals, AstraZeneca Rare Disease,
Abstract
Impact of nirogacestat on pain, a key symptom in patients with desmoid tumors (DT): Results from the phase 3 DeFi study.Org: IQVIA Inc., Bratislava, Slovakia, IQVIA, Amsterdam, Netherlands, SpringWorks Therapeutics, Universität Heidelberg, Mannheim Cancer Center (MCC),
Abstract
Real-world response endpoints in patients with mNSCLC treated with chemotherapy across real-world datasets.Org: Friends of Cancer Research, Washington, DC, American Society of Clinical Oncology, COTA Inc, Syapse, Tempus Labs, Inc.,
Abstract
Real-world utilization pattern of pexidartinib in patients with tenosynovial giant cell tumor (TGCT).Org: Daiichi Sankyo Inc., IQVIA, Amsterdam, Netherlands, Sarcoma Medical Oncology Service, Memorial Sloan Kettering Cancer Center,
Abstract
5-YEAR TRAJECTORIES OF URATE-LOWERING THERAPY AND IMPACT OF COLCHICINE ON CARDIOVASCULAR RISK: REAL-LIFE DATA ON 70,000+ PATIENTSOrg: IQVIA, Amsterdam, Netherlands, Université de Paris,
Abstract
A MACHINE LEARNING ANALYSIS OF FACTORS PREDICTING ORGAN DAMAGE PROGRESSION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS USING THE SPANISH SOCIETY OF RHEUMATOLOGY LUPUS REGISTRY (RELESSER)Org: Eli Lilly and Company Ltd, IQVIA, Amsterdam, Netherlands,
Abstract
ALGORITHM IDENTIFYING CHRONIC INFLAMMATORY DISEASES TREATED BY BIOTHERAPY AND/OR TARGETED SYNTHETIC TREATMENTS IN OUTPATIENT CARE IN FRANCE: FEASIBILITY, PRELIMINARY RESULTS, AND IMPACT OF COVID-19Org: IQVIA, Amsterdam, Netherlands, Lariboisiere Hospital - APHP, St Louis Hospital, Bichat Hospital,
Abstract
BASELINE CHARACTERISTICS OF REAL-WORLD PSORIATIC ARTHRITIS PATIENTS TREATED WITH GUSELKUMAB OR IL-17 INHIBITORS: RESULTS FROM THE ONGOING MULTINATIONAL PSABIOND STUDYOrg: Janssen MEA, Dubai Healthcare City, Dubai, United Arab Emirates, JSS Medical Research, IQVIA, Amsterdam, Netherlands, Janssen Cilag Global Medical Affairs, Immunology Global Medical Affairs, Issy les Moulineaux, France,